8 results for "organoid"
Neuronal Population Effects of Ketamine on Human Brain Organoids
OpenAlex – March 10, 2026
Summary
Ketamine significantly alters human brain organoid dynamics, silencing neuronal networks while maintaining firing rates. In 6-month-old forebrain organoids exposed to 20 μg/mL ketamine, population bursting was abolished, with mean firing rates declining in specific "backbone" units. Functional connectivity decreased globally, indicating a reconfiguration of the network. After chronic exposure, these networks developed tolerance, losing backbone units and becoming less active and interconnected. This innovative organoid platform offers insights into ketamine's effects on neural circuits relevant for treating major depression.
Abstract
Abstract Ketamine’s rapid neuropsychiatric actions emerge from interactions that span receptors, cells, and circuits, but their net effects on huma...
Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy
ACS Medicinal Chemistry Letters – October 10, 2025
Summary
A breakthrough in psychedelic therapy reveals a novel psilocin-psilocybin cocrystal that enhances neuroplasticity and functional activity. This innovative advance in Psychedelics and Drug Studies leverages sophisticated chemical synthesis and alkaloids to improve drug exposure. Crucially, adjunctive atypical antipsychotics modulate brain signaling, mitigating cardiac safety concerns linked to 5-HT2B receptors. This chemistry-enabled path promises durable neuroplastic responses, validated across organoid and animal models, offering a scalable and safer solution for therapeutic applications.
Abstract
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypica...
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Front Dement – August 04, 2025
Summary
Psychedelic compounds appear to positively reshape key proteins in human brain cells, offering a novel avenue for Alzheimer's treatment. Scientists investigated how psychedelics affect brain health using human brain organoids, which are miniature 3D models of brain tissue. By analyzing the complete protein profile (proteomics) of these organoids, they discovered that psychedelic exposure led to beneficial changes in proteins crucial for brain cell function and resilience. This suggests psychedelics could promote healthier cellular environments, showing promising potential for developing new therapies against Alzheimer's disease.
Abstract
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
LSD Modulates Proteins Involved in Cell Proteostasis, Energy Metabolism and Neuroplasticity in Human Cerebral Organoids.
ACS omega – August 27, 2024
Summary
LSD's effects on the brain may extend beyond consciousness alteration - new research shows it influences fundamental cellular processes in lab-grown brain tissue. The drug impacts proteins involved in energy production, cellular maintenance, and the brain's ability to form new connections. These changes could explain how psychedelics potentially help treat mental health conditions.
Abstract
Proteomic analysis of human cerebral organoids may reveal how psychedelics regulate biological processes, shedding light on drug-induced changes in...
Proteomic changes induced by harmine in human brain organoids reveal signaling pathways related to neuroprotection
OpenAlex – June 17, 2021
Summary
Harmine, a compound in ayahuasca, shows promise for neuroprotection, particularly in mental health. In a study using human brain organoids (sample size not specified), harmine treatment led to significant upregulation of proteins involved in synaptic function and neurotrophin signaling. Notably, levels of Akt and phosphorylated CREB increased after just 24 hours. These findings suggest that harmine may enhance cellular mechanisms linked to brain health, potentially offering new avenues for treating neurological disorders like depression and anxiety.
Abstract
Abstract Harmine is a β-carboline found in Banisteriopsis caapi , a constituent of ayahuasca brew. Ayahuasca is consumed as a beverage in native Am...
Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders
International Journal of Molecular Sciences – September 07, 2020
Summary
Promising early neuroscience results are emerging for treating depression, which impacts millions globally. Clinical trials using Psilocybin and deep brain stimulation targeting the Habenula show potential. These interventions, central to Psychiatry and Medicine, modulate serotonergic systems, influencing neurotransmitter receptor behavior. Advanced neuroimaging is crucial to understand these psychedelic-induced changes at a molecular level, alongside exploring chemical synthesis and alkaloids. This integrated approach in Psychology aims to refine treatments, offering hope for a significant impact on depression's economic burden.
Abstract
Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of...
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT.
Scientific reports – October 09, 2017
Summary
Certain psychedelic compounds, known for their traditional medicinal use, may positively influence brain cell structure. Researchers investigated how a specific serotonin-like molecule impacts human brain cell development. Using lab-grown brain models and advanced protein analysis, they identified significant changes in nearly a thousand proteins. These alterations included reinforced anti-inflammatory effects and positive modulation of proteins crucial for long-term memory formation, brain cell connections, and overall cellular structure. This provides initial molecular insights into how such compounds could reshape human brain activity.
Abstract
Dimethyltryptamines are entheogenic serotonin-like molecules present in traditional Amerindian medicine recently associated with cognitive gains, a...
Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N,N-dimethyltryptamine
OpenAlex – February 13, 2017
Summary
A striking 934 out of 6,728 identified proteins in human cerebral organoids showed differential expression after treatment with the hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). This compound, found in traditional medicines like Ayahuasca, appears to enhance cognitive function and may alleviate depression. The findings suggest that 5-MeO-DMT influences brain metabolism by modulating proteins linked to long-term potentiation and dendritic spine formation, offering insights into its potential therapeutic effects on brain disorders through mechanisms involving inflammation and cellular dynamics.
Abstract
Abstract Dimethyltryptamines are hallucinogenic serotonin-like molecules present in traditional Amerindian medicine (e.g. Ayahuasca) recently assoc...